Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ANGLE device offers breakthrough in detecting and predicting spread of prostate cancer

The new results were presented at the World CDx Europe conference in London
ANGLE device offers breakthrough in detecting and predicting spread of prostate cancer
Parsortix could be a valuable weapon in the fight against the killer disease

ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) collaboration with Barts Cancer Institute (BCI) has shown the company’s Parsortix system is useful in detecting and predicting the spread of prostate cancer.

The new results, presented at the World CDx Europe conference in London, suggest that using Parsortix in combination with existing assessment methods is potentially more effective than the current approach.

Metastasis, the spread of cancer to another part of the body, is responsible for over 90% of cancer-related deaths. 

So, a key issue in the treatment of prostate cancer is to determine whether the cancer has been contained or whether it is continuing to progress to metastasis. In the latter case, the earlier treatment can be deployed the better.

The gold standard for detecting metastasis is imaging. 

However, this cannot be predictive as it is imaging metastatic sites that have already developed. 

With Parsortix it may be possible to improve the prediction of the likely development of metastasis early and/or to identify the presence of metastasis before it can be seen by imaging technologies. 

This would benefit patients by allowing early treatment and by reducing harmful exposure to radioactive imaging.

"This is another significant milestone in progressing the development of Parsortix for the treatment of prostate cancer,” said ANGLE founder Andrew Newland.

“The new results further support the expansion of the potential clinical application to include both early and late stage prostate cancer."

View full AGL profile View Profile

ANGLE plc Timeline

Related Articles

Drugs
May 03 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
genomics.jpg
October 04 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.
cancer cells
July 12 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use